Humacyte, Inc. financial data

Symbol
HUMA, HUMAW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2525 East North Carolina Highway 54, Durham, North Carolina
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Alpha Healthcare Acquisition Corp. (to 8/26/2021)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 612 % -24%
Debt-to-equity 1.09K % +927%
Return On Equity -1.15K % -1132%
Return On Assets -96.8 % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 119M shares +15.4%
Common Stock, Shares, Outstanding 119M shares +15.4%
Entity Public Float 178M USD +7.41%
Common Stock, Value, Issued 12K USD +20%
Weighted Average Number of Shares Outstanding, Basic 119M shares +15.3%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +15.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 83.7M USD +19.5%
General and Administrative Expense 23.1M USD -1.34%
Operating Income (Loss) -107M USD -14.3%
Nonoperating Income (Expense) -32.8M USD -776%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -140M USD -57.5%
Earnings Per Share, Basic -1.26 USD/shares -44.8%
Earnings Per Share, Diluted -1.26 USD/shares -46.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 93.6M USD -18.4%
Cash, Cash Equivalents, and Short-term Investments 80.4M USD -47.1%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 96.1M USD -20.3%
Property, Plant and Equipment, Net 24.8M USD -13%
Operating Lease, Right-of-Use Asset 600K USD -14.3%
Other Assets, Noncurrent 815K USD
Assets 138M USD -17.7%
Accounts Payable, Current 6.01M USD +154%
Employee-related Liabilities, Current 4M USD +9.33%
Accrued Liabilities, Current 8.95M USD +36.2%
Liabilities, Current 17.8M USD +55.9%
Deferred Income Tax Liabilities, Net 1.52M USD -18.3%
Operating Lease, Liability, Noncurrent 600K USD 0%
Other Liabilities, Noncurrent 1.26M USD +42%
Liabilities 167M USD +55.7%
Retained Earnings (Accumulated Deficit) -626M USD -28.7%
Stockholders' Equity Attributable to Parent -28.3M USD -146%
Liabilities and Equity 138M USD -17.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -27.3M USD -46.7%
Net Cash Provided by (Used in) Financing Activities 62.8M USD
Net Cash Provided by (Used in) Investing Activities -391K USD +66.1%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 119M shares +15.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 35.1M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 93.9M USD -18.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 152M USD +15.7%
Deferred Tax Assets, Gross 153M USD +15.2%
Operating Lease, Liability 632K USD -9.71%
Depreciation 5.18M USD -16.3%
Payments to Acquire Property, Plant, and Equipment 391K USD -66.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -140M USD -57.5%
Lessee, Operating Lease, Liability, to be Paid 889K USD -10.6%
Property, Plant and Equipment, Gross 58.7M USD +2.09%
Operating Lease, Liability, Current 56K USD +9.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 105K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 105K USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 257K USD -17.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 105K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 80.8M USD +19%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 105K USD 0%
Additional Paid in Capital 598M USD +9.18%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.52M USD -18.3%
Share-based Payment Arrangement, Expense 6.07M USD -10.7%
Interest Expense 6.72M USD +3.85%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%